Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.36
NSPR's Cash to Debt is ranked lower than
59% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. NSPR: 1.36 )
Ranked among companies with meaningful Cash to Debt only.
NSPR' s 10-Year Cash to Debt Range
Min: 0.34  Med: 5026.60 Max: No Debt
Current: 1.36
Equity to Asset 0.18
NSPR's Equity to Asset is ranked lower than
92% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. NSPR: 0.18 )
Ranked among companies with meaningful Equity to Asset only.
NSPR' s 10-Year Equity to Asset Range
Min: -0.65  Med: 0.24 Max: 0.78
Current: 0.18
-0.65
0.78
F-Score: 4
Z-Score: -15.35
M-Score: 3.58
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -841.26
NSPR's Operating margin (%) is ranked lower than
90% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 3.07 vs. NSPR: -841.26 )
Ranked among companies with meaningful Operating margin (%) only.
NSPR' s 10-Year Operating margin (%) Range
Min: -840.95  Med: -318.67 Max: -228.66
Current: -841.26
-840.95
-228.66
Net-margin (%) -896.10
NSPR's Net-margin (%) is ranked lower than
91% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.65 vs. NSPR: -896.10 )
Ranked among companies with meaningful Net-margin (%) only.
NSPR' s 10-Year Net-margin (%) Range
Min: -890.53  Med: -464.70 Max: -244.25
Current: -896.1
-890.53
-244.25
ROE (%) -376.94
NSPR's ROE (%) is ranked lower than
98% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. NSPR: -376.94 )
Ranked among companies with meaningful ROE (%) only.
NSPR' s 10-Year ROE (%) Range
Min: -521.08  Med: -405.67 Max: -363.41
Current: -376.94
-521.08
-363.41
ROA (%) -155.08
NSPR's ROA (%) is ranked lower than
93% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 0.05 vs. NSPR: -155.08 )
Ranked among companies with meaningful ROA (%) only.
NSPR' s 10-Year ROA (%) Range
Min: -436.36  Med: -282.07 Max: -155.85
Current: -155.08
-436.36
-155.85
ROC (Joel Greenblatt) (%) -3177.97
NSPR's ROC (Joel Greenblatt) (%) is ranked lower than
91% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 3.52 vs. NSPR: -3177.97 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NSPR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8439.86  Med: -2853.62 Max: -1484.91
Current: -3177.97
-8439.86
-1484.91
Revenue Growth (3Y)(%) -41.00
NSPR's Revenue Growth (3Y)(%) is ranked lower than
93% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. NSPR: -41.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NSPR' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 0.00 Max: -41
Current: -41
EBITDA Growth (3Y)(%) -8.80
NSPR's EBITDA Growth (3Y)(%) is ranked lower than
65% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. NSPR: -8.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NSPR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -8.80 Max: 390.5
Current: -8.8
0
390.5
EPS Growth (3Y)(%) -9.30
NSPR's EPS Growth (3Y)(%) is ranked lower than
62% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. NSPR: -9.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NSPR' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: -9.30 Max: 418
Current: -9.3
0
418
» NSPR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

NSPR Guru Trades in

NSPR Guru Trades in

Q1 2015

NSPR Guru Trades in Q1 2015

Jim Simons 65,900 sh (New)
» More
Q2 2015

NSPR Guru Trades in Q2 2015

Jim Simons 402,600 sh (+510.93%)
» More
» Details

Insider Trades

Latest Guru Trades with NSPR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.68
NSPR's P/B is ranked lower than
80% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 3.01 vs. NSPR: 6.68 )
Ranked among companies with meaningful P/B only.
NSPR' s 10-Year P/B Range
Min: 2.87  Med: 16.00 Max: 420
Current: 6.68
2.87
420
P/S 4.32
NSPR's P/S is ranked lower than
60% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. NSPR: 4.32 )
Ranked among companies with meaningful P/S only.
NSPR' s 10-Year P/S Range
Min: 3.8  Med: 17.36 Max: 98.18
Current: 4.32
3.8
98.18
Current Ratio 1.64
NSPR's Current Ratio is ranked lower than
72% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 2.44 vs. NSPR: 1.64 )
Ranked among companies with meaningful Current Ratio only.
NSPR' s 10-Year Current Ratio Range
Min: 0.13  Med: 2.14 Max: 4.68
Current: 1.64
0.13
4.68
Quick Ratio 1.47
NSPR's Quick Ratio is ranked lower than
63% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. NSPR: 1.47 )
Ranked among companies with meaningful Quick Ratio only.
NSPR' s 10-Year Quick Ratio Range
Min: 0.13  Med: 1.80 Max: 4.28
Current: 1.47
0.13
4.28
Days Inventory 264.41
NSPR's Days Inventory is ranked lower than
79% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 129.48 vs. NSPR: 264.41 )
Ranked among companies with meaningful Days Inventory only.
NSPR' s 10-Year Days Inventory Range
Min: 127.34  Med: 135.33 Max: 315.56
Current: 264.41
127.34
315.56
Days Sales Outstanding 115.28
NSPR's Days Sales Outstanding is ranked lower than
79% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 69.92 vs. NSPR: 115.28 )
Ranked among companies with meaningful Days Sales Outstanding only.
NSPR' s 10-Year Days Sales Outstanding Range
Min: 82.25  Med: 130.26 Max: 138.85
Current: 115.28
82.25
138.85

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 20.00
NSPR's Price/Net Current Asset Value is ranked lower than
84% of the 207 Companies
in the Global Medical Devices industry.

( Industry Median: 6.33 vs. NSPR: 20.00 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NSPR' s 10-Year Price/Net Current Asset Value Range
Min: 5.26  Med: 24.22 Max: 76.25
Current: 20
5.26
76.25
Price/Tangible Book 6.67
NSPR's Price/Tangible Book is ranked lower than
65% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 4.01 vs. NSPR: 6.67 )
Ranked among companies with meaningful Price/Tangible Book only.
NSPR' s 10-Year Price/Tangible Book Range
Min: 4.57  Med: 19.70 Max: 390
Current: 6.67
4.57
390
Price/Median PS Value 0.23
NSPR's Price/Median PS Value is ranked higher than
97% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. NSPR: 0.23 )
Ranked among companies with meaningful Price/Median PS Value only.
NSPR' s 10-Year Price/Median PS Value Range
Min: 0.32  Med: 1.22 Max: 5.21
Current: 0.23
0.32
5.21
Earnings Yield (Greenblatt) (%) -149.36
NSPR's Earnings Yield (Greenblatt) (%) is ranked lower than
98% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.50 vs. NSPR: -149.36 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NSPR' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -241.22  Med: 0.00 Max: 0
Current: -149.36
-241.22
0

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 5 12
EPS($) -0.22 -0.14
EPS without NRI($) -0.22 -0.14

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
InspireMD Inc was organized in the State of Delaware on February 29, 2008 as Saguaro Resources, Inc. On March 28, 2011, it effectuated a 1-for-3 forward stock split and changed its name from Saguaro Resources, Inc. to InspireMD, Inc. It is an medical device company focusing on the development and commercialization of its proprietary stent platform technology, MGuard. MGuard provides embolic protection in stenting procedures by placing a micron mesh sleeve over a stent. The Company's initial products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). According to the TYPHOON STEMI trial and the SOS SVG Trial of patients with acute myocardial infarction and saphenous vein graft coronary interventions, 7.5% to 44% experience adverse cardiac events, including cardiac death, heart attack, and restenting of the artery. When performing stenting procedures in patients with acute coronary symptoms, interventional cardiologists face a difficult dilemma in choosing between bare-metal stents, which have a high rate of restenosis (formation of new blockages), and drug-eluting (drug-coated) stents, which have a high rate of late thrombosis (formation of clots months or years after implantation), require administration of anti-platelet drugs for at least one year post procedure, are more costly than bare-metal stents and have additional side effects. It intends to use its MGuard technology in a broad range of coronary related situations in which complex lesions are required and make it an industry standard for treatment of acute coronary syndromes. It also intends to apply its technology to develop additional products used for other vascular procedures, specifically carotid (the arteries that supply blood to the brain) and peripheral (other arteries) procedures. The Company markets its products through distributers in international markets, mainly in Europe and Latin America.
» More Articles for NSPR

Headlines

Articles On GuruFocus.com
InspireMD Reports 4 Significant Insider Buys Apr 19 2013 

More From Other Websites
InspireMD to Present at the Rodman & Renshaw 17th Annual Global Investment Conference Sep 01 2015
InspireMD to Present at the Rodman & Renshaw 17th Annual Global Investment Conference Sep 01 2015
INSPIREMD, INC. Financials Aug 15 2015
InspireMD Reports Financial Results for the Second Quarter Ended June 30, 2015 Aug 06 2015
InspireMD Announces Distribution Partnership of its CGuardTM Embolic Prevention System with... Aug 06 2015
INSPIREMD, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of... Aug 05 2015
InspireMD Reports Financial Results for the Second Quarter Ended June 30, 2015 Aug 05 2015
InspireMD Announces Distribution Partnership of its CGuard™ Embolic Prevention System with... Aug 05 2015
Q2 2015 InspireMD Inc Earnings Release - After Market Close Aug 05 2015
InspireMD to Report Financial Results for the Second Quarter Ended June 30, 2015 on Wednesday,... Aug 03 2015
INSPIREMD, INC. Files SEC form 8-K, Other Events Jul 17 2015
InspireMD to Report Financial Results for the Second Quarter Ended June 30, 2015 on Wednesday,... Jul 14 2015
InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award Jul 07 2015
InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award Jul 07 2015
INSPIREMD, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Jul 06 2015
3 Stocks Under $10 Making Big Moves Jun 16 2015
4 Stocks Under $10 Making Big Moves Jun 04 2015
InspireMD’s CGuard™ Highlighted at Clinical Presentation at EuroPCR 2015 Conference May 22 2015
INSPIREMD, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and... May 22 2015
InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference May 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK